共 50 条
- [1] DKN-01 and tislelizumab plus chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trialANNALS OF ONCOLOGY, 2022, 33 (07) : S1103 - S1104Klempner, S. J.Chao, J.Uronis, H.Sirard, C.Kagey, M.Baum, J.Song, J.Wang, J.Sonbol, M. B.Wainberg, Z. A.Ajani, J. A.
- [2] DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trialANNALS OF ONCOLOGY, 2021, 32 : S1048 - S1049Klempner, S. J.Sirard, C.Chao, J.Chiu, V.Mahalingam, D.Uronis, H.Kagey, M.Baum, J.Dayyani, F.Song, J.Wang, J.Iqbal, S.Tejani, M.Sonbol, M. B.Scott, A. J.Wainberg, Z.Ajani, J. A.
- [3] DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish TrialJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Klempner, Samuel J.Chao, JosephUronis, Hope ElizabethSirard, Cynthia A.Kagey, MichaelBaum, JasonSong, JamesWang, JinKim, In-HoLee, Keun WookOh, Do-YounSonbol, Bassam BassamWainberg, Zev A.Ajani, Jaffer A.
- [4] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484Lee, Keun-WookMoehler, Markus H.Cunningham, DavidWainberg, Zev A.Uronis, Hope ElizabethOh, Do-YounKim, In-HoShim, Byoung YongSym, Sun JinAltura, Rachel A.Stilian, Melissa C.Parker, Elizabeth C.Klempner, Samuel J.
- [5] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Xu, Rui-huaArkenau, Hendrik-TobiasBang, Yung-JueDenlinger, Crystal S.Kato, KenTabernero, JosepWang, JinLi, JiangCastro, HenryMoehler, Markus H.
- [6] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286Moehler, Markus H.Kato, KenArkenau, Hendrik-TobiasOh, Do-YounTabernero, JosepCruz-Correa, MarciaWang, HongWeiXu, HuiLi, JiangYang, SiluXu, Rui-hua
- [7] Phase (Ph) II study of zanidatamab plus chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)ANNALS OF ONCOLOGY, 2021, 32 : S1044 - S1045Ku, G.Elimova, E.Denlinger, C. S.Mehta, R.Lee, K-W.Iqbal, S.Kang, Y-K.Oh, D-Y.Rha, S. Y.Kim, Y. H.Seol, Y. M.Mwatha, T.Grim, J.Ajani, J. A.
- [8] DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survivalJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)Klempner, Samuel J.Bendell, Johanna C.Villaflor, Victoria MeucciTenner, Laura LaNielStein, StaceyNaik, Girish S.Sirard, Cynthia A.Kagey, MichaelChaney, Marya F.Strickler, John H.
- [9] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Xu, Rui-huaArkenau, Hendrik-TobiasBang, Yung-JueDenlinger, Crystal S.Kato, KenTabernero, JosepWang, JinLi, JiangCastro, HenryMoehler, Markus Hermann
- [10] RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinomaANNALS OF ONCOLOGY, 2020, 31 : S97 - S98Xu, R.Arkenau, T.Bang, Y.Denlinger, C.Kato, K.Tabernero, J.Wang, J.Li, J.Castro, H.Moehler, M.